Daxor Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Daxor şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

-0.06%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.06%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	US$0.030
Ödeme oranı	0%

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: DXR şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: DXR şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Daxor Piyasaya Karşı Temettü Getirisi

DXR temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (DXR)	0%
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (DXR) (3 yıla kadar)	n/a

Önemli Temettü: DXR şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, DXR şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: DXR US piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: DXR herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Daxor Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Daxor Corporation, Annual General Meeting, Jul 15, 2024

Nasdaq Staff Determines Daxor Complies with Nasdaq’s Audit Committee Requirement Set in Listing Rule 5605

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

New minor risk - Profit margin trend

New minor risk - Financial data availability

Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis

Investor sentiment deteriorates as stock falls 16%

Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Investor sentiment improves as stock rises 20%

Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers

Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting

JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®

Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jul 11, 2023

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Investor sentiment deteriorates as stock falls 26%

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorated over the past week

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $2.000007 million.

Daxor Corporation Study Demonstrates Significant Clinical Utility of Daxor's Blood Volume (Bva-100(R)) Diagnostic in the Evaluation of Heart Failure

Investor sentiment deteriorated over the past week

Daxor Corporation Announces New Data Validating Benefits of BVA-100 Diagnostic Blood Test in Reducing Hospital Length of Stay (LOS) for Heart Failure (HF) Patients

Daxor Corporation to Report Q2, 2022 Results on Aug 25, 2022

Daxor reports Q2 results

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor Corporation, Annual General Meeting, Jun 23, 2022

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

Daxor Corporation Announces New Data Demonstrating the Importance and Clinical Utility of Daxor’s Bva-100 Blood Test in Heart Failure (Hf) Patients Published in the Journal of Cardiac Failure

Daxor Corporation Announces Patient Enrollment Completion and Updates Data Analysis

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Daxor Corporation Provides Update on American College of Cardiology (ACC) Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

Daxor Corporation Announces the Initiation of A Multi-Center Clinical Trial with Two Veterans Affairs Medical Centers to Evaluate Blood Volume Analysis Guided Management of Acute Decompensated Heart Failure Utilizing the BVA-100 Blood Test

Daxor Corporation Announces Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

Daxor Corporation Announces Novel Fluorescent Tracer and Phase-Two US Air Force Contract Award of $750,000 for Point-Of-Care Optical Blood Volume Analyzer

Revenue and earnings miss expectations

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

New 90-day low: US$11.49

Daxor Corporation Announces New Data from the University of Hawaii John A. Burns School of Medicine Showing the BVA-100 Blood Test

Daxor Corporation Announces New Distribution Agreement with L1 Enterprises Government Distributor

New 90-day low: US$12.10

New 90-day low: US$12.55

Wake Forest Baptist Health Joins Multicenter Covid-19 Bva-100 Blood Test Study

New 90-day low: US$13.85

New 90-day low: US$14.61

Daxor Corporation Announces Compelling New Data Demonstrating Further Beneficial Use of Blood Volume Analysis Technology Presented During the Heart Failure Society of America’s Virtual Annual Scientific Meeting 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin